Group One Trading, L.P. Kezar Life Sciences, Inc. Transaction History

Group One Trading, L.P.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	SELL	$2.31 - $3.06 $211,108 - $279,650	-91,389 Reduced 87.18%	13,442 $32,000
Q1 2023 May 12, 2023	BUY	$3.13 - $7.31 $328,121 - $766,314	104,831 New	104,831 $328,000
Q3 2022 Nov 09, 2022	SELL	$7.99 - $10.75 $529,113 - $711,886	-66,222 Reduced 71.75%	26,072 $224,000
Q2 2022 Aug 11, 2022	BUY	$4.58 - $17.13 $402,508 - $1.51 Million	87,884 Added 1992.83%	92,294 $763,000
Q1 2022 May 12, 2022	BUY	$12.3 - $18.33 $54,243 - $80,835	4,410 New	4,410 $73,000
Q4 2021 Feb 11, 2022	SELL	$7.44 - $16.72 $4,493 - $10,098	-604 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$4.85 - $9.73 $2,929 - $5,876	604 New	604 $5,000
Q2 2021 Aug 10, 2021	SELL	$4.93 - $6.46 $986 - $1,292	-200 Closed	0 $0
Q1 2021 May 12, 2021	SELL	$5.24 - $6.99 $23,291 - $31,070	-4,445 Reduced 95.69%	200 $1,000
Q3 2020 Nov 12, 2020	BUY	$4.36 - $5.5 $3,052 - $3,850	700 Added 17.74%	4,645 $22,000
Q2 2020 Aug 13, 2020	BUY	$3.6 - $7.75 $14,202 - $30,573	3,945 New	3,945 $20,000

38.4M

13.8K

600

Ticker KZR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,369,504
Market Cap $510M
Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

Stay updated on Group One Trading, L.P. with notifications on news.